Obesity and thyroid cancer

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 2, 2011, Pages 555-564

  Mijovic, Tamara ^a   How, Jacques ^b   Payne, Richard J ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Adiponectin; BMI; COX 2; Cytokines; Endocrinology; Etiology; Igf 1; Insulin; Leptin; Obesity; Pathogenesis; Review; Sex Hormones; Thyroid Neoplasm; Toxins; TSH; Vitamin D

Indexed keywords

ADIPONECTIN; ANDROSTENEDIONE; CALCITRIOL; CYCLOOXYGENASE 2; ERBIUM; ESTRADIOL; ESTROGEN; ESTRONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; MITOGENIC AGENT; ORAL CONTRACEPTIVE AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SEX HORMONE BINDING PROTEIN; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN; THYROTROPIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VITAMIN D; CYTOKINE;

ADIPOSE TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BODY FAT; BODY MASS; BODY SIZE; BODY WEIGHT; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CYTOKINE RELEASE; DIFFERENTIATED THYROID CANCER; DISEASE ASSOCIATION; ENERGY BALANCE; EPIDEMIC; ESTROGEN SYNTHESIS; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY FOLLICLE CELL; POSTMENOPAUSE; SUBCLINICAL HYPOTHYROIDISM; THYROID CANCER; THYROID CARCINOMA; THYROID CELL; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID FUNCTION; THYROID NODULE; THYROTROPIN BLOOD LEVEL; TUMOR PROMOTION; FEMALE; MALE; METABOLISM; REVIEW; THYROID TUMOR;

CYTOKINES; FEMALE; GONADAL STEROID HORMONES; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; OBESITY; THYROID NEOPLASMS; THYROTROPIN; VITAMIN D;

EID: 79955978311     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Tremblay M, Katzmarzyk PT, Willms JD: Temporal trends in overweight and obesity in Canada, 1981-1996. Int J Obes 26, 538-543 (2002)
2. Flegal K, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults 1999- 2000. JAMA 288, 1723-1727 (2002)
3. Irigaray P, Newby JA, Lacomme S, Belpomme D: Overweight/obesity and cancer genesis: more than a biological link. Biomed Pharmacother 61, 665-678 (2007)
4. Pothiwala P, Jain SK, Yaturu S: Metabolic Syndrome and Cancer. Metabolic Syndrome and Related Disorders 7, 279-287 (2009)
5. Renehan A, Tsyan M, Egger M, Heller RF, Zwahlen M: Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371, 569-578 (2008)
6. Yumuk V and Yumuk PF: What links obesity to cancer? Indoor Built Environ 14, 527-532 (2005)
7. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS: Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. Am J Clin Nutr 86(supp), 858S-866S (2007)
8. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK: A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12, 13-21 (2001)
9. Meinhold C, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS, Berrington de Gonzalez A: Nonradiation Risk Factors for Thyroid Cancer in the US Radiologic Technologists Study. Am J Epidemiol 171, 242- 252 (2010)
10. Davies L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295, 2164-2167 (2006)
11. Liu S, Semenciw R, Ugnat A-M, Mao Y: Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effect. Br J Cancer 85, 1335-1339(2001)
12. Kent W, Hall SF, Isotalo PA, et al. Kent W, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA: Increased incidence of differentiated thyroid cancer and detection of subclinical disease. CMAJ 177, 1357-1361(2007)
13. How J and Tabah R: Explaining the increasing incidence of differentiated thyroid cancer. CMAJ 177, 1383-1384(2007)
14. D?Avanzo B, La Vecchia C, Franceschi S, Negri E, Talamini R: History of thyroid diseases and subsequent thyroid cancer risk. Cancer Epidemiol Biomarkers Prev 4, 193-199(1995)
15. Glattre E, Haldorsen T, Berg JP, Stensvold I, Solvoll K: Norwegian case-control study testing the hypothesis that seafood increases the risk of thyroid cancer. Cancer Causes Control 4, 11-16(1993)
16. Hallquist A, Hardell L, Degerman A, Boquist L: Thyroid cancer: reproductive factors, previous diseases, drug intake, family history and diet. A case control study. Eur J Cancer Prev 3, 481-488(1994)
17. Kolonel L, Hankin JH, Wilkens LR, Fukunaga FH, Hinds MW: An epidemiologic study of thyroid cancer in Hawaii. Cancer Causes Control 1, 223-234(1990)
18. Levi F, Franceschi S, La Vecchia C, Negri E, Gulie C, Duruz G, Scazziga B: Previous thyroid disease and risk of thyroid cancer in Switzerland. Eur J Cancer 27, 85-88(1991)
19. Linos A, Linos DA, Vgotza N, Souvatzoglou A, Koutras DA: Does coffee consumption protect against thyroid disease? Acta Chir Scand 155, 317-320(1989)
20. McTiernan A, Weiss NS, Daling JR: Incidence of thyroid cancer in women in relation to previous exposure to radiation therapy and history of thyroid disease. J Natl Cancer Inst. 73, 575-581(1984)
21. Preston-Martin S, Bernstein L, Pike MC, Maldonado AA, Henderson BE: Thyroid cancer among young women related to prior thyroid disease and pregnancy history. Br J Cancer 55, 191-195(1987)
22. Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF Jr: A population-based case control study of thyroid cancer. J Natl Cancer Inst 79, 1-12(1987)
23. Wingren G, Hatschek T, Axelson O: Determinants of papillary cancer of the thyroid. Am J Epidemiol 138, 482-491(1993)
24. Preston-Martin S, Jin F, Duda MJ, Mack WJ: A casecontrol study of thyroid cancer in women under age 55 in Shanghai (People?s Republic of China). Cancer Causes Control 4, 431-440(1993)
25. Dal Maso L, La Vecchia C, Franceschi1 S, Preston- Martin S, Ron E, Levi F, Mack W, Mark SD, McTiernan A, Kolonel L, Mabuchi K, Jin F, Wingren G, Galanti MR, Hallquist A, Glattre E, Lund E, Linos D, Negri E: A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control 11, 137-144(1990)
26. Mack W, Preston-Martin S, Bernstein L, Qian D: Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. Ann Epidemiol. 12, 395-401(2002)
27. Guignard R, Truong T, Rougier Y, Baron-Dubourdieu D, Guenel P: Alcohol drinking, tobacco smoking, and anthropometric characteristics as risk factors for thyroid cancer: A countrywide case-control study in New Caledonia. Am J Epidemiol 166, 1140-1149(2007)
28. Brindel P, Doyon F, Rachédi F, Boissin JL, Sebbag J, Shan L, Chungue V, Bost-Bezeaud F, Petitdidier P, Paoaafaite J, Teuri J, de Vathaire F: Anthropometric factors in differentiated thyroid cancer in French Polynesia: A casecontrol study. Cancer Causes Control. 20, 581-590(2009)
29. Suzuki T, Matsuo K, Hasegawa Y, Hiraki A, Kawase T, Tanaka H, Tajima K: Anthropometric factors at age 20 years and risk of thyroid cancer. Cancer Causes Control 19, 1233-1242(2008)
30. Iribarren C, Haselkorn T, Tekawa IS, Friedman GD: Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 93, 745-750(2001)
31. Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK: Obesity and incidence of cancer: A large cohort study of over 145 000 adults in Austria. Br J Cancer 93, 1062-1067(2005)
32. Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JFJ: Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15, 35-43(2004)
33. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr: Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 17, 901-909(2006)
34. Oh S, Yoon YS, Shin SA: Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23, 4742-4754(2005)
35. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L: Risk factors for malignant diseases: A cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev 6, 863-873(1997)
36. Engeland A, Tretli S, Akslen LA, Bjorge T: Body size and thyroid cancer in two million Norwegian men and women. Br J Cancer 95, 366-370(2006)
37. Romiti A, Buzzetti R, Salandri A, Festuccia F, Giovannini CA, Santella S, Montesani C, Giovannini C: Tumori della tiroida nell'obesita. Minerva Endocrinologica. 1998(23):27-29.(1998)
38. Festuccia F, Romiti A, Buzzetti R, Salandri A, Montesani C, Giovannini C, Giovannini C: Tireopatie latenti nell'obesita. Recenti Progressi in Medicina 89, 165-168(1998)
39. Mijovic T, How J, Pakdaman M, Rochon L, Gologan O, Hier MP, Black MJ, Young J, Tamilia M, Payne RJ: Body Mass Index in the Evaluation of Thyroid Cancer Risk. Thyroid 19, 467-472(2009)
40. Randi G, Ferraroni M, Talamini R, Garavello W, Deandrea S, Decarli A: Glycemic index, glycemic load and thyroid cancer risk. Ann Oncol 19, 380-383(2007)
41. Hard G: Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Environ Health Perspect 106, 427-436(1998)
42. Ciampolillo A, De Tullio C, Perlino E, Maiorano E: The IGF-I Axis in Thyroid Carcinoma. Current Pharmaceutical Design 13, 729-735(2007)
43. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H: Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metabolic Syndrome and Related Disorders 7, 375-380(2009)
44. Russell J, Engiles JB, Rothstein JL: Proinflammatory Mediators and Genetic Background in Oncogene Mediated Tumor Progression. J Immunol 172, 4059-4067(2004)
45. Cleary M, Grossmann ME: Obesity and Breast Cancer: The Estrogen Connection. Endocrinol 150, 2537-2542(2009)
46. Cornetta A, Russell JP, Cunnane M, Keane W, Rothstein JL: Cyclooxygenase-2 Expression in Human Thyroid Carcinoma and Hashimoto's Thyroiditis. Laryngoscope 112, 238-242(2002)
47. Delage B, Rullier A, Capdepont M, Rullier E, Cassand P: The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr J 6, 1-10(2007)
48. Garofalo C and Surmacz E: Leptin and cancer. J Cell Physiol 207, 12-22(2006)
49. Akinci M, Kosova F, Cetin B, Aslan S, Ari Z, Cetin A: Leptin levels in thyroid cancer. Asian J Surg 32, 216-223(2009)
50. Cheng SP, Chi CW, Tzen CY, Yang TL, Lee JJ, Liu TP, Liu CL: Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 147, 847-853(2010)
51. Kelesidis T, Kelesidis I, Chou S, Mantzoros C: Narrative review: The role of leptin in human physiology: emerging clinical applications. Ann Intern Med 152, 93- 100(2010)
52. Bluher S and Mantzoros C: Leptin in humans: lessons from translational research. Am J Clin Nutr 89(suppl), 991S-997S(2009)
53. Uddin S, Bavi P, Siraj AK, Ahmed M, Al-Rasheed M, Hussain AR, Ahmed M, Amin T, Alzahrani A, Al-Dayel F, Abubaker J, Bu R, Al-Kuraya KS: Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocrine-related cancer 17, 191- 202(2010)
54. Nillni EA, Vaslet C, Harris M, Hollenberg A, Bjørbak C, Flier JS: Leptin regulates prothyrotropin-releasing hormone biosynthesis: evidence for direct and indirect pathways. J Biol Chem 275, 36124-36133(2000)
55. Nowak KW, Kaczmarek P, Mackowiak P, Ziolkowska A, Albertin G, Ginda WJ, Trejter M, Nussdorfer GG, Malendowicz LK: Rat thyroid gland expresses the long form of leptin receptors, and leptin stimulates the function of the gland in euthyroid nonfasted animals. Int J Mol Med 9, 31-34(2002)
56. Bray G: The underlying basis for obesity: relationship to cancer. J Nutr 11 Suppl, 3451S- 3455S(2002)
57. Chen G, Vlantis AC, Zeng Q, van Hasselt CA: Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets 8, 367-377(2008)
58. Barnett J: The relationship between obesity and breast cancer risk and mortality. Nutr Rev 61, 73-76(2003)
59. Banu K, Govindarajulu P, Aruldhas M: Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH function. . Endocr Pathol 12, 315-327(2001)
60. Chan E, Sepkovic DW, Yoo Browne HJ, Yu GP, Schantz SP: A hormonal association between estrogen metabolism and proliferative thyroid disease. . Otolaryngol Head Neck Surg 134, 893-900(2006)
61. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M: Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. . J Clin Endocrinol Metab 86, 1072-1077(2001)
62. La Vecchia C, Ron E, Franceschi S, Dal Maso L, Mark SD, Chatenoud L, Braga C, Preston-Martin S, McTiernan A, Kolonel L, Mabuchi K, Jin F, Wingren G, Galanti MR, Hallquist A, Lund E, Levi F, Linos D, Negri E: A pooled analsis of case-control studies of thyroid cancer III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 10, 157-166(1999)
63. Negri E, Dal Maso L, Ron E, La Vecchia C, Mark SD, Preston-Martin S, McTiernan A, Kolonel L, Yoshimoto Y, Jin F, Wingren G, Rosaria Galanti M, Hardell L, Glattre E, Lund E, Levi F, Linos D, Braga C, Franceschi S: A pooled analysis of case-control studies of thyroid cancer II. Menstrual and reproductive factors Cancer Causes Control 10, 143-155(1999)
64. Akslen L, Nilssen S, Kvale G: Reproductive factors and risk of thyroid cancer. A prospective study of 63,090 women from Norway. Br J Cancer 65, 772-774(1992)
65. Brindel P, Doyon F, Rachédi F, Boissin JL, Sebbag J, Shan L, Chungue V, Sun LYK, Bost-Bezeaud F, Petitdidier P, Paoaafaite J, Teuri J, de Vathaire F: Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in naitive women in French Polynesia: A population-based case-control study. Am J Epidemiol 167, 219-229(2007)
66. Memon A, Darif M, Al-Saleh K, Suresh A: Epidemiology of reproductive and hormonal factors in thyroid cancer: evidence from a case-control study in the middle east. Int J Cancer 97, 82-89(2002)
67. Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, McTiernan A, Kolonel L, Mark SD, Mabuchi K, Jin F, Wingren G, Galanti R, Hallquist A, Glattre E, Lund E, Levi F, Linos D, Ron E.A pooled analysis of case-control studies of thyroid cancer IV. Benigh thyroid disease. Cancer Causes Control 10, 583-595(1999)
68. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA: Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investi- gated by fine-needle aspiration. J Clin Endocrinol Metab 91, 4295-4301(2006)
69. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H: Higher serum thyroid stimulating hormone level in thyroid nodule patients i associated with greater risk of differenciated thyroid cancer and advances tumor stage. J Clin Endocrinol Metab 93, 809-814(2008)
70. Jonklass J, Nsouli-Maktabi H, Soldin SJ: Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid 18, 943-952(2008)
71. Manji N, Boelaert K, Sheppard MC, Holdert RL, Gough and Franklyn JA: Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. Clin Endocrinol 64, 125-128(2006)
72. Fox C, Pencina MJ, D?Agostino RB, Murabito JM, Seely EW, Pearce EN, Vasan RS: Relations of thyroid function to body weight. Arch Intern Med 168, 587-592(2008)
73. Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L, Jørgensen T: Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 90, 4019-4024(2005)
74. De Pergola G, Ciampolillo A, Paolotti S, Trerotoli P, Giorgino R: Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. Clin Endocrinol 67, 265-269(2007)
75. Dietlein M, Kahaly G, Kobe C, Schmidt M, Derwahl KM, Schicha H: Obesity, energy regulation and thyroid function: is borderline elevated TSH-level the cause or secondary phenomenon of obesity. Nuclear-Medizin. 47, 181-187(2008)
76. Bell N, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S: Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 76, 370-373(1985)
77. Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH: Low circulating vitamin D in obesity. Calcif Tissue Int 43, 199-201(1988)
78. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF: Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72, 690-693(2000)
79. Arunabh S, Pollack S, Yeh J, Aloia JF: Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 88, 157-161(2003)
80. Parikh S, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, Yanovski JA: The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 89, 1196-1199(2004)
81. Ford E, Ajani UA, McGuire LC, Liu S: Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 28, 1228-1230(2005)
82. Konradsen S, Ag H, Lindberg F, Hexeberg S, Jorde R: Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. Eur J Nutr 47, 87-91(2008)
83. Liu W, Asa SL, Fantus G, Walfish PG, Ezzat S: Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN=Akt- dependent and -independent pathways. Am J Pathol 160, 511-519(2002)
84. Okano K, Usa T, Ohtsuru A, Tsukazaki T, Miyazaki Y, Yonekura A, Namba H, Shindoh H, Yamashita S: Effect of 22-oxa-1,25-dihydroxyvitamin D3 on human thyroid cancer cell growth. Endocr J 46, 243-252(1999)
85. Penna-Martinez M, Ramos-Lopez E, Stern J, Hinsch N, Hansmann ML, Selkinski I, Grünwald F, Vorländer C, Wahl RA, Bechstein WO, Zeuzem S, Holzer K, Badenhoop K: Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid 19, 623-628(2009)
86. Stepien T, Krupinski R, Sopinski J, Kusdak K, Komorowski J, Lawnicka H, Stepien H: Decreased 1-25 dihydroxyvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer. Arch Med Res 41, 190-194(2010)
87. Markaki I, Linos D, Linos A: The influence of dietary patterns on the development of thyroid cancer. Eur J Cancer 38, 1912-1919(2003)
88. Bosetti C, Negri E, Kolonel L et al: A pooled analysis of case-control studies of thyroid cancer. VII Cruciferous and other vegetables (International). Cancer Causes Control 13, 765-775(2002)
89. Salabe G: Aetiology of thyroid cancer: an epidemiological overview. Thyroidol Clin 6, 11-19(1994)
90. Truong T, Baron-Dubourdieu D, Rougier Y, Guenel P: Role of dietary iodine and cruciferous vegetables in thyroid cancer: A countrywide case-control study in New Caledonia. Cancer Causes Control 21, 1183-1192(2010)